Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome-Reference-Cited by-同舟云学术

Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome

Published:2021-06-01 Issue:6 Volume:157 Page:700
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Hirotsu Kelsey E.¹,Neal Tatiana M.¹,Khodadoust Michael S.²,Wang Jennifer Y.¹³,Rieger Kerri E.¹³,Strelo Jenna¹,Hong Eric¹,Kim Youn H.¹²,Kwong Bernice Y.¹

Affiliation:

1. Department of Dermatology, Stanford University School of Medicine, Palo Alto, California

2. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California

3. Department of Pathology, Stanford University School of Medicine, Stanford, California

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2778631/jamadermatology_hirotsu_2021_oi_210015_1623774324.45393.pdf

Reference21 articles.

1. Mogamulizumab Versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.;Kim;Lancet Oncol,2018

2. CCR4 and its ligands: from bench to bedside.;Yoshie;Int Immunol,2015

3. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.;Ni;Clin Cancer Res,2015

4. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.;Sugiyama;Proc Natl Acad Sci U S A,2013

5. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.;Ishida;J Clin Oncol,2012

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mogamulizumab‐assoziierter Rash – Fallserie und aktuelle Literatur;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-08

2. Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature;Expert Review of Anticancer Therapy;2024-07-23

3. Mogamulizumab‐associated rash – Case series and review of the literature;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-06-25

4. Arzneimittelexantheme unter Immun- und zielgerichteter onkologischer Therapie;Die Dermatologie;2024-05-21

5. Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome;Dermatology Reports;2024-05-07